
Communication from the GPhC regarding Regulatory Concerns
Communication from the GPhC regarding Regulatory Concerns Regarding the Supply and Promotion of Weight-Management Medicines – Mounjaro®, Wegovy® and Related GLP-1 Therapies
Communication from the GPhC regarding Regulatory Concerns Regarding the Supply and Promotion of Weight-Management Medicines – Mounjaro®, Wegovy® and Related GLP-1 Therapies
Pharmacists need to check their Professional Indemnity Insurance to ensure that it covers them for the services they are providing, and to ensure that the level of cover is sufficient.
The MHRA has reviewed its current approach to contacting UK Licence Holders who may be implicated by USFDA Warning Letters
As part of maintaining professional vigilance and regulatory compliance across pharmacy services, PCL would like to draw attention to several critical issues recently highlighted by the General Pharmaceutical Council (GPhC).
The UK is entering a new phase of innovation in how it regulates, assesses, and adopts new medicines—and it’s a development the global pharmaceutical and biopharmaceutical industry cannot afford to overlook.
Pharmacists, remember to direct their virtual patients to the Pharmacy First Survey to leave their feedback on the service.